Get started
Author

David Tébar-García

Observed names: D Tébar-García, David Tebar-García, David Tébar García, Tebar García, D., Tebar-García, David, Teábar García, David, Tébar García, David
ORCID: 0000-0003-4176-5985
Observed ORCID: 0000-0003-4176-5985
OpenAlex ID: A5078872097
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
2022 · María del Mar Noblejas-López, Lucía Gandullo-Sánchez, et al. · International Journal of Molecular Sciences · 31
PDF
TACkling Cancer by Targeting Selective Protein Degradation
2023 · María del Mar Noblejas-López, David Tébar-García, et al. · Pharmaceutics · 27
PDF
MZ1 co-operates with trastuzumab in HER2 positive breast cancer
2021 · María del Mar Noblejas-López, Cristina Nieto-Jiménez, et al. · Journal of Experimental & Clinical Cancer Research · 21
PDF
Pathogenic Microenvironment from Diabetic–Obese Visceral and Subcutaneous Adipocytes Activating Differentiation of Human Healthy Preadipocytes Increases Intracellular Fat, Effect of the Apocarotenoid Crocetin
2021 · Lesgui Alviz, David Tebar-García, et al. · Nutrients · 7
PDF
Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al. · Cancer Research · 3
PDF
Discovery and evaluation of novel biomarkers reveal dasatinib as a potential treatment for a specific subtype of Triple-Negative Breast Cancer
2024 · D Ortega-Álvarez, D Tébar-García, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2
PDF
Association between homocysteine levels and arterial stiffness in the adult population: a systematic review and meta-analysis
2025 · Alicia Saz-Lara, Andrea Del Saz-Lara, et al. · Postgraduate Medical Journal · 1
Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
2020 · Miriam Nuncia Cantarero, Leticia Serrano-Oviedo, et al. · Journal of Clinical Oncology · 1
Supplementary Figure S7 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Figure 5 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Supplementary Figure S3 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Supplementary Figure S2 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Supplementary Figure S4 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Supplementary Figure S11 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Figure 4 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Figure 3 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Figure 6 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Figure 1 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Supplementary Table S3 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Supplementary Table S2 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Figure 2 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Supplementary Figure S5 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Supplementary Table S5 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Supplementary Figure S9 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Supplementary Figure S8 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
2026 · Daniel Ortega-Álvarez, David Tébar-García, et al.
Works count: 46
Citation count: 92
H-index: 4
I10-index: 3
Year
Topic
Type